Business Context and Reporting Period
Cocrystal Pharma, Inc. filed this Form 8-K on May 18, 2018, reporting the unregistered sale of equity securities. The filing details the conversion of outstanding 8% convertible notes into common stock following a recent public offering.
Key Financial Metrics
- Debt: The Company now has no debt following the full conversion of its notes.
- Equity Issuance: A total of 1,085,105 shares of common stock were issued upon conversion.
- Conversion Price: Notes were converted at $1.90 per share, matching the offering price of the recent public offering.
- Revenue, Profit, Cash Flow, Margins, Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change is the elimination of the Company's outstanding 8% convertible notes. Previously, these notes were due in November 2019 and January 2020. The conversion involved:
- A $500,000 note held by the Company's Chairman (converted May 10, 2018).
- A $500,000 note held by an entity where the Chairman serves as a director.
- A $1 million note held by Opko Health, Inc., a public company with significant director overlap.
Outlook, Risks, and Unusual Items
The issuance of common stock was exempt from registration pursuant to Section 3(a)(9) of the Securities Act of 1933. The conversion was approved by a resolution of two disinterested directors. The filing does not contain specific forward-looking guidance, management commentary on future operations, or new risk factors beyond the transaction details.
Investor Verification Checklist
- Verify the total number of shares issued (1,085,105) and the resulting dilution impact.
- Confirm the complete elimination of debt obligations previously due in 2019 and 2020.
- Review the related party transactions involving the Chairman and Opko Health, Inc.
- Check the Company's cash position post-conversion to ensure liquidity remains sufficient for operations.